25906 grey3 long3

Syndecion, LLC

Syndecion makes high quality, robust, and synthetic single-domain antibodies for clinical, diagnostic and research purposes.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Baltimore, MD, USA
  • Currency USD
  • Founded February 2012
  • Employees 2
  • Website syndecion.com

Company Summary

Syndecion makes high quality, robust antibodies for clinical, research, and diagnostic use. We compete in the highly competitive antibody market by 1.Making an antibody that is robust and easy to produce, 2.Using a powerful antibody discovery method for high quality antibodies and 3.Focusing on high value therapeutics that are not actively addressed by large pharmaceutical companies. Our customers are biotechnology and pharmaceutical companies.


  • Photo

    Dr King is an immunologist and a veterinarian. He has experience in vaccine development, immunity to infectious diseases, vaccine clinical trials, in vivo gene delivery and making hybridomas for monoclonal antibody production. Prior to Syndecion, he was CSO of Cyto Pulse Sciences.

  • Dr. Deitz is a molecular biologist with diverse experience in the fields of cell biology, biochemistry, viral immunology, and vaccinology In addition to his scientific skills, Dr. Deitz has experience in both project management and comprehensive study design. At Syndecion, he is focused on improving current biotechnologies, with emphasis on antibody technologies, and developing methods and reagents to fill empty niches in the antibody market.


  • Default avatar
    Evan Langert
    Default avatar
    Flower &Desiderio Financial Group, LLC

Previous Investors

  • Default avatar
    Alan D King
    Default avatar
    Jean K Southard
    Default avatar
    Kathleen J Jones